Alexis Ji, Ph.D.

Partner at Illumina Ventures

Alexis Ji joined Illumina Ventures as a partner in 2016. She brings 12 years of experience in research and venture investment in the genomics and pharmaceutical industries. At Illumina Ventures, Alexis focuses on investing in early-stage genomics technology platforms and applications in life science tools, diagnostics, therapeutics, and digital health.


Prior to Illumina Ventures, Alexis was a principal at WuXi Apptec Corporate Venture Fund and then WuXi Healthcare Ventures, a U.S.-China cross-border life science venture capital firm, where she focused on investments in therapeutics and medtech companies in the U.S. Alexis was instrumental in investments in Twist Bioscience, 23andme, Juno Therapeutics, Syros Pharmaceuticals, Unity Biotechnology, Vivace Therapeutics, Medeor Therapeutics, Ideaya Therapeutics, and Lumo Bodytech. Before joining WuXi, Alexis was a venture investment consultant at ARCH Venture Partners, where she evaluated early-stage life science and physical science opportunities and was involved in the founding of Twist Bioscience and the investment in Nextcode Health, and provided operating assistance to Boreal Genomics and PixelEXX Systems.


Earlier in her career, Alexis worked as a senior scientist at Merck in early drug discovery, at Roche in virology translational research and clinical trial development, and at Life Technologies in molecular diagnostics and next-generation sequencing.


Alexis earned her Ph.D. in Molecular Genetics from Washington University in St. Louis, where her thesis was on non-coding RNA discovery. Alexis holds an MBA from University of Chicago Booth School of Business, and a Bachelor in Biochemistry from Shandong University.